Scarecrow Incorporated Secures World's First Patent for Canine Cardiac Supplement Pinfenon (S) (R)
| Summary/Static | Details |
|---|---|
| Why in the news? | Pinfenon (S) (R) - First Patent for Canine Cardiac Disorder Treatment |
| Patent Name | Treatment and prophylactic drug for lowering ANP in dogs and manufacturing methods |
| Patent Number | P7542838 |
| Patent Holder | Scarecrow Incorporated |
| Inventors | Hiroshi Okawa, Hiroshi Koie |
| Patent Registration Date | August 23, 2024 |
| Application Date | February 15, 2024 |
| Main Ingredient | French maritime pine bark extract (Pycnogenol), fermented sesame extract, yeast extract |
| Form | 5mm tablets |
| Target Disease | Mitral regurgitation (common in small dogs) |
| Biomarker | Atrial natriuretic peptide (ANP), key heart health indicator |
| Clinical Study | 27 dogs with mitral regurgitation across 15 hospitals in Japan, 30-day duration |
| Clinical Results | Significant decrease in ANP levels, improvement in breathing difficulty |
| Regulatory Approval | Approved as a drug by the Japan Patent Office |
| Product Applications | Treatment drug, preventative supplement for cardiac issues; also applicable in food, shampoos, and essences |
| Scientific Backing | Over 800 research papers globally support the efficacy of Pycnogenol |